Less than a tenth of individuals who could benefit from obesity jabs including Wegovy are able to get them, warns the WHO as it publishes its inaugural guidance on the medications.
Given over a billion people worldwide currently obese, it is calling for more widespread and fairer availability to this class of drugs.
According to projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"Our latest guidelines recognises that obesity is a long-term condition that can be addressed with comprehensive and lifelong care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are significant obstacles to broad access to the injections that can assist patients in reducing considerable weight, notes the organization.
Weight-Loss Drug Scarcity
Even in the current most favorable case, the manufacturing of these medications might only reach approximately 100 million people – under 10% of those who need them, according to the WHO.
The recommendation urges nations and manufacturers to expand availability, via measures including voluntary licensing.
The intellectual property rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is scheduled to end in several nations in 2026.
The Way Obesity Injections Operate
The injections mimick a biological compound to delay gastric emptying, suppress the appetite and boost feelings of fullness so people eat less.
People commonly begin shedding pounds in the initial weeks of beginning the weekly injections.
Evidence indicates patients may regain a significant portion a year later of discontinuing the medication, as their normal hunger come back.
To be carrying excess weight elevates your likelihood for developing medical conditions, such as diabetes, heart disease, brain attack, and certain malignancies.
Excess weight concerns people in countries worldwide and was responsible for millions of fatalities worldwide in 2024, per the health agency.
